


# PATENT COOPERATION TREATY

05/08

From the  
INTERNATIONAL SEARCHING AUTHORITY

To:

see form PCT/ISA/220



## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1)

Date of mailing  
(day/month/year) see form PCT/ISA/210 (second sheet)

Applicant's or agent's file reference  
see form PCT/ISA/220

**FOR FURTHER ACTION**  
See paragraph 2 below

International application No.  
PCT/US2005/001069

International filing date (day/month/year)  
13.01.2005

Priority date (day/month/year)  
19.01.2004

International Patent Classification (IPC) or both national classification and IPC  
A61K38/11, A61K38/08, A61P15/06

Applicant  
FERRING B.V.

**1. This opinion contains indications relating to the following items:**

- ☒ Box No. I Basis of the opinion
- ☐ Box No. II Priority
- ☒ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☐ Box No. VIII Certain observations on the international application

**2. FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

**3. For further details, see notes to Form PCT/ISA/220.**

Name and mailing address of the ISA:



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized Officer

Escolar Blasco, P

Telephone No. +49 89 2399-7331



**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.  
PCT/US2005/001069

---

**Box No. I Basis of the opinion**

---

1. With regard to the **language**, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.  
☐ This opinion has been established on the basis of a translation from the original language into the following language , which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).
2. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
  - a. type of material:  
☐ a sequence listing  
☐ table(s) related to the sequence listing
  - b. format of material:  
☐ in written format  
☐ in computer readable form
  - c. time of filing/furnishing:  
☐ contained in the international application as filed.  
☐ filed together with the international application in computer readable form.  
☐ furnished subsequently to this Authority for the purposes of search.
3. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.  
PCT/US2005/001069

**Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application,
- ☒ claims Nos. 10-19, in respect of IA

because:

- ☒ the said international application, or the said claims Nos. 10-19 relate to the following subject matter which does not require an international preliminary examination (*specify*):

**see separate sheet**

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☒ no international search report has been established for the whole application or for said claims Nos. -
- ☐ the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:
  - the written form ☐ has not been furnished
  - ☐ does not comply with the standard
  - the computer readable form ☐ has not been furnished
  - ☐ does not comply with the standard
- ☐ the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.
- ☐ See separate sheet for further details

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.  
PCT/US2005/001069

---

**Box No. V Reasoned statement under Rule 43b/s.1(a)(I) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

---

**1. Statement**

Novelty (N)	Yes: Claims	
	No: Claims	1-7,9-16,18-19
Inventive step (IS)	Yes: Claims	
	No: Claims	1-19
Industrial applicability (IA)	Yes: Claims	1-9
	No: Claims	

**2. Citations and explanations**

**see separate sheet**

**Comments on Item III**

Claims 10-19 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

**Comments on item V**

1. The following documents (D) are referred to in this communication; the numbering will be adhered to in the rest of the procedure. If not indicated otherwise, the present communication refers to the passages cited in the International Search Report.  
D1: WO 94/25485 A  
D2: ZINGG HANS H ET AL: "The oxytocin receptor." TRENDS IN ENDOCRINOLOGY AND METABOLISM, vol. 14, no. 5, July 2003, pages 222-227  
D3: EP-A-0 346 068  
D4: ABBRESCIA K (REPRINT) ET AL: "Complications of second and third trimester pregnancies" EMERGENCY MEDICINE CLINICS OF NORTH AMERICA, VOL. 21, NO. 3, PP. 695-+. PUBLISHER: W B SAUNDERS CO, INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA, August 2003  
D5: DATABASE TOXCENTER [Online] 2001, COSMI, E. V.: "Pharmacologic treatment of preterm labour" retrieved from STN Database accession no. 2003:308202
2. Oxytocin antagonists have been developed for treating oxytocin induced vascular contractility; in particular, the inhibition of preterm labour is their most common medical use (atosiban is marketed for this same indication). Therefore, claims 1, 10 and 19 lacks novelty: see for instance D1, D2, D3, D4 and D5.
3. Many known oxytocin antagonists are peptides: see D1 or D3, which anticipate the

subject-matter of claims 2-3 and D2, which destroys the novelty of claims 2-4 and 11-13.

4. D1 and D3 disclose peptidic oxytocin receptor antagonists which can be used for treating hypertension. Hence, they anticipate also the subject-matter of claims 5 and 14.
5. D5 mentions the use of oxytocin antagonists in the treatment of preeclampsia, i.e. it discloses the additional features of claims 6, 7, 9, 15, 16 and 18.
6. Hence, the subject-matter of claims 1-7 and 9 lacks novelty over different prior art documents. The additional feature of claims 8 and 17 has not been specifically disclosed in any of the available documents; however, it does not render inventive the subject-matter of the claims to which it refers.
7. For the assessment of the present claims 10-19 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.